Conference abstract · 16 Nov 2017
Conference abstractPublished 22 Oct 2018
Harmonization By Doing: Looking to the next decade
Duke Clinical Research Institute, USA; Duke University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The US-Japan Medical Device Harmonization By Doing (HBD) program has enabled the US FDA, Japan PMDA, international regulators, academia, and industry to develop practical standards for global clinical trials. This has facilitated development of novel cardiovascular devices and helped overcome regulatory barriers that have historically delayed timely medical device approvals in both countries. The collaborative activity is expanding its scope to create additional synergies in global medical device development, particularly for early feasibility studies, non-cardiovascular therapeutic areas and pediatric medical device applications. Encouraging single global clinical trial protocols will facilitate device evaluation in both the US and Asia by improving the timeliness and cost-effective generation of more informative clinical datasets for pre-market, and potentially post market evaluation. This will reduce the data requirements for device development programs by reducing redundant data collection. For example, the Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS) registry and the US Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registry, both collect and analyze clinical and laboratory data from patients receiving mechanical circulatory support devices for end-stage heart failure. The complementary datasets in these registries provide valuable information for improving the treatment of advanced heart failure patients in both countries. Clinical trial programs, such as the HARMONEE (NCT02073565) and COAST (NCT02132611) trials, represent a new approach to evaluating efficacy and safety in a global environment. Future directions will extend these initiatives and their benefits to additional countries and facilitate patient access to new medical device technology worldwide.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Sep 2016
A decade later, another look at what role in global spread of H5N1 played up-regulation by host cell dioxin of gene encoding type A influenza virus NS1 binding protein
Conference abstract · 12 Sep 2016
A decade later, another look at what role in global spread of H5N1 played upregulation by host cell dioxin of gene encoding type A influenza virus NS1 binding protein
Article · 14 Feb 2026
Will CRISPR-Cas9 Revolutionize Genetic Medicine in the Next Decade?
Article · 28 Mar 2025
The Future of Pharmacy and Pharmacology: Innovations Shaping the Next Decade
More from this journal
The newest in Clinical and Experimental Cardiology.
Short communication · 4 Aug 2026
An effective determination method for aortic valve replacement through minimally invasive lower median sternotomy
Conference abstract · 15 Jun 2026
Speckle Tracking Echocardiography for Early Identification of Chemotherapy-Induced Cardiotoxicity
Conference abstract · 15 Jun 2026
Coronary CT Angiography as a First-Line Diagnostic Tool for Stable Chest Pain: Clinical Outcomes from a Multicenter Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical and Experimental Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “David F Kong”

